Pharmacogenomics and IBD: TPMT and thiopurines

Inflammatory Bowel Diseases

Volumn 10, Issue 7 SUPPL. 1, 2004, Pages

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; INOSINE TRIPHOSPHATE; MERCAPTOPURINE; NUCLEOTIDE PYROPHOSPHATASE; THIOPURINE METHYLTRANSFERASE;

ALLELE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; ENTERITIS; ENZYME ACTIVITY; FLU LIKE SYNDROME; GENETIC REGULATION; GENETIC VARIABILITY; HEPATITIS; HUMAN; LEUKOPENIA; NAUSEA; PANCREATITIS; PHARMACOGENOMICS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STEADY STATE; VOMITING;

EID: 1542515337     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200402001-00008     Document Type: Article

References (31)

1. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
2. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433.
3. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.
4. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002;51:143-146.
5. Chan GL, Erdmann GR, Gruber SA, et al. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol. 1990;30:358-363.
6. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999;117:527-535.
7. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
8. Ansari AR, Marinaki T, Arenas M, et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Gastroenterology 2003;124:A-11.
9. Lee D, Szumlanski C, Houtman J, et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metabolism & Disposition. 1995;23:398-405.
10. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997;62:60-73.
11. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. [comment] Ann Intern Med. 1997;126: 608-614.
12. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000; 118:1025-1030.
13. Lennard L, Rees CA, Lilleyman JS, et al, Childhood leukaemia: a relationship between intracellular 6- mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:359-363.
14. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clinical Pharmacology & Therapeutics. 1989;46:149-154.
15. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-718.
16. Seddik M, Texier F, Ferrari N, et al. Thiopurine S-methyltransferase genotyping does not predict azathioprine-induced myelosuppression in Crohn's disease. Gastroenterology 2003;124:A-1311.
17. Curvers W, Derijks L, Stikkers P, et al. No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy for inflammatory bowel disease. Gastroenterology 1993;124:A-377.
18. Curvers W, Gilissen L, Derijks L, et al. Pharmacokinetic analysis of 6-mercaptopurine in patients with inflammatory bowel disease. Gastroenterology. 2003;124:.(In Press)
19. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. [comment] Arch Dermatol. 1995;131: 193-197.
20. Snow JL, Gibson LE. A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol. 1995;32:114-116.
21. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med. 1992;85:752-756.
22. Verhoef VL, Fuller SA, Morris AJ. Individual variation of nucleoside triphosphate pyrophosphohydrolase activity in human erythrocytes, granulocytes, lymphocytes, and platelets. Biochem Genet. 1980;18:235-245.
23. Lin S, McLennan AG, Ying K, et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J Biol Chem. 2001;276:18695-18701.
24. Sumi S, Marinaki AM, Arenas M, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002;111:360-367.
25. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet. 2002;47:620-622.
26. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. [comment] J Clin Invest. 2003;111:1133-1145.
27. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut. 1996;39: 401-406.
28. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
29. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
30. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut. 2001;49:665-670.
31. Belaiche J, Desager JP, Horsmans Y, et al. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol. 2001;36:71-76.